Home›Earnings›Analyst Ratings›Analysts lift price targets for AbbVie as healthcare d…

Analysts lift price targets for AbbVie as healthcare dividends draw buyers

The stock has risen about 15% in 2026, and its upcoming ex-dividend date is Oct. 15.

Reported · Written up by our desk · Analyst Ratings

MarketBeat Ratings highlights AbbVie, Johnson & Johnson, and Merck as large-cap healthcare dividend plays, pairing growing payouts with ongoing pipeline and regulatory catalysts heading into 2027.

For AbbVie, the outlet cites a 2.62% dividend yield and an annual dividend of $6.92, with a dividend increase track record spanning 53 years and annualized 5-year dividend growth of 6.80%.

MarketBeat Ratings also notes AbbVie is up about 15% in 2026, and that after the company’s Q2 2026 earnings report in July, several analysts raised their price targets.

The outlet adds that optimism was reinforced as the U.S. Food & Drug Administration advanced approvals, and it lists an upcoming AbbVie ex-dividend date of Oct. 15.

More like this

Sources